Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (IRIS)
Phase II Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (The IRIS Trial: Immune Checkpoint Inhibitor Rechallenge Involving Sarilumab)
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Danielle Wendler
- 电话号码:410-502-5140
- 邮箱:JHCTN@jhmi.edu
研究联系人备份
- 姓名:Chelsea Miralles
- 电话号码:410-955-9923
- 邮箱:cmirall1@jhmi.edu
学习地点
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
接触:
- Danielle Wendler
- 电话号码:410-502-5140
- 邮箱:JHCTN@jhmi.edu
-
接触:
- Chelsea Miralles
- 电话号码:4109559923
- 邮箱:cmirall1@jhmi.edu
-
首席研究员:
- Aliyah Pabani, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Eligible patients include patients with malignancy treated with ICI, who have been diagnosed with a clinically significant irAE (grade 1-3 attributed to ICI per CTCAE v6.0) requiring interruption of ICI by the treating physician. This study is limited to patients with the following specific irAEs as IL-6R blockade has demonstrated effectiveness in these conditions. Specific toxicities eligible for inclusion are; arthritis, colitis, PMR, nephritis, pneumonitis, hepatitis, myositis
-
The risk/benefit profile must favor ICI rechallenge as deemed per treating oncologist
-
The irAE must have improved to grade 1 by CTCAE criteria v6.0 for at least 1 week (exception for patients who have endocrinopathies which will typically require lifelong hormone supplementation)
-
Be willing and able to provide informed consent/assent for the trial
-
Be ≥18 years of age on the day of signing informed consent
-
Female subject of childbearing potential must have a negative urine or serum pregnancy test within 2 weeks prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
-
Women of child-bearing potential (WOCBP):
- Agree to use contraception while participating in this study, and for a period of 6 months following last dose of Sarilumab or ICI, as effects of these agents on the developing human fetus are unknown. Men whose partner is a WOCBP must also agree to use contraception during this period. Negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within two weeks of registration. Women must not be breastfeeding or plan to breastfeed for the duration of therapy or 6 months after.
-
Males must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 3 months after last dose of sarilumab, 120 days even if he has undergone a successful vasectomy
-
Have adequate organ function as described below
- Absolute neutrophil count (ANC) ≥500/mm3
- Platelets ≥ 50,000/mm3
- AST/ALT <=3× institutional upper limit of normal
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Completed informed consent process, including signing Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form.
-
Willing and able to comply with clinical trial instructions and requirements. Subjects must be competent to report AEs, understand the drug dosing schedule, and use of medications to control AEs
Exclusion Criteria:
- History of grade 4 irAE (attributed to ICI per CTCAE v6.0)
- History of cardiovascular or neurologic immune related adverse event
- Active or serious infections
- History of latent Tuberculosis (TB) or uncontrolled hepatitis B/C
- History of gastrointestinal perforation or diverticulitis
- Severe hepatic impairment (AST, ALT >3xULN; total bilirubin >1.5xULN)
- Significant hematological abnormalities
- On prednisone equivalent >10mg prior to first dose of trial treatment
- History of immunodeficiency disorder
- Treatment with a non-biologic immunosuppressive or immune-modulating drug (e.g. methotrexate, azathioprine, mycophenolate, cyclosporine, hydroxychloroquine, penicillamine) at time of enrollment
- Treatment with other immune-modulating biologic agents (e.g TNF-alpha inhibitors) within 8 weeks prior to enrollment
- History of anaphylaxis or IgE-mediated hypersensitivity to sarilumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to sarilumab.
- The subject must meet all of the inclusion criteria and none of the exclusion criteria.
No eligibility waivers will be granted.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Sarilumab with ICI
Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be dosed by investigator's choice per standard of care for malignancy. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator. |
Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety as assessed by Absence of any grade ≥2 Immune Related Adverse Event (irAE)
大体时间:From enrollment to the end of treatment at 53 weeks
|
Absence of any grade ≥2 Immune Related Adverse Event (irAE) in the 3 months after ICI rechallenge, defined as grade ≥2 adverse event attributed to ICI by CTCAE v6.0 |
From enrollment to the end of treatment at 53 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability as assessed by occurrence of adverse events
大体时间:From enrollment to the end of treatment at 53 weeks
|
Safety and tolerability will be measured by occurrence of grade ≥3 adverse events as measured by CTCAE v6.0 and patient reported outcomes (PROs) as assessed by PRO-CTCAE v1.0. |
From enrollment to the end of treatment at 53 weeks
|
|
Absence of Serious immune-related adverse event
大体时间:From enrollment to the end of treatment at 53 weeks
|
To assess to the safety of Immune Checkpoint Inhibitor (ICI) rechallenge with sarilumab with respect to serious irAE of grade ≥2 in patients with a history of non- cardiovascular and non-neurologic clinically significant irAEs. |
From enrollment to the end of treatment at 53 weeks
|
|
Efficacy as assessed by progression free survival
大体时间:From enrollment to the end of treatment at 53 weeks
|
Cancer outcomes will be measured by progression free survival (PFS). PFS is defined as the time from first dose of sarilumab + ICI rechallenge until investigator-assessed radiological progressive disease (PD) or death, whichever comes first. |
From enrollment to the end of treatment at 53 weeks
|
|
Efficacy as assessed by Overall survival
大体时间:From enrollment to the end of treatment at 53 weeks
|
Cancer outcomes will be measured by overall survival (OS).Overall survival is defined as the time from first dose of sarilumab + ICI rechallenge until death. |
From enrollment to the end of treatment at 53 weeks
|
合作者和调查者
调查人员
- 首席研究员:Aliyah Pabani, MD、Johns Hopkins University
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- J2687
- 15845 (其他赠款/资助编号:Robert A. Winn Excellence in Clinical Trials Award)
- IRB00559848 (其他标识符:Johns Hopkins IRB)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.